when will bpc 157 be banned This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the FDA make An FDA advisory committee is

The TRIUMPH-4 Phase 3 trial in obesity with knee osteoarthritis (Bays et al., NEJM 2025) reported 28.7% mean weight loss at 68 weeks at the 12 mg dose, plus a 75.8% reduction in WOMAC knee pain scores

Category 2 is the FDA's designation for bulk drug substances nominated for compounding consideration that have been identified as presenting potential safety risks and are currently ineligible for routine compounding under Section 503A

The exact cause is unclear, but it may relate to systemic absorption of the corticosteroid or individual sensitivity

Avoid in active malignancies, the protocol shouldnt exacerbate undiagnosed tumors